Ryeqo was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) last October based on results from the LIBERTY programme, consisting of two 24-week phase 3 clinical trials.

Around 1,000 women in England a year with endometriosis will soon have access to the first daily oral therapy after Gedeon Richter's Ryeqo was cleared for NHS use. This morning, NICE recommended ...

Get Instant Summarized Text (Gist) Linzagolix, an oral GnRH antagonist, will soon be available on the NHS for endometriosis patients unresponsive to standard treatments. By suppressing estrogen ...